Immunai
Latest round
- Series C
Last raised
- Oct 2021
Total raised
- $285M
Investors
- 12
About Immunai
Immunai Inc.Founded in 2018 in New York, US, Immunai Inc. specializes in decoding immunity through its innovative platform. The company has undergone strategic pivots to enhance its focus on multiomic data integration. The founders include Ansuman Satpathy, Danny Wells, and Luis Voloch, while Noam Solomon serves as CEO.Immunai's offerings center around its advanced platform for decoding immunity, utilizing high-quality multiomic data from clinical and preclinical samples. Key solutions include Target Discovery for identifying disease-related targets, Preclinical Evaluation for prioritizing drug candidates, and Clinical Trial Optimization for enhancing drug understanding.Immunai generates revenue through partnerships and collaborations with biopharmaceutical companies and research institutions, offering subscription-based access to its platform and data services. Clients enter into multi-year agreements for these services, including consultations leveraging Immunai's machine learning expertise. The company aims to launch new products designed to enhance capabilities in immune-related drug discovery. Additionally, Immunai is targeting expansion in new markets, focusing on increasing its presence in Europe and Asia by 2023.
Who invested in Immunai
12 investors across 3 rounds
See all investors in Immunai
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Immunai
Who invested in Immunai?
Immunai has 12 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Immunai raised?
Immunai has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Immunai last raise money?
Immunai's most recent round on record is a Series C, in Oct 2021.
What does Immunai do?
Immunai is a biotechnology company.
Where is Immunai headquartered?
Immunai is headquartered in New York, US.
Which VCs invest in companies like Immunai?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Immunai's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Immunai? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.